Imedrix Inc.
Analysis completed on 3/23/2026
Imedrix shows strong real-world utility and technical innovation with its FDA-cleared KardioScreen ECG device and reported clinical usage across 15 countries. However, the submission heavily underperforms in evidence of traction and response quality due to vague and unsubstantiated claims (e.g., audience reach stated as 'everyone' and traction claimed as 'most people have used my product').
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline